BSI-201 Enters Phase 3 in Metastatic Triple Negative Breast Cancer
17 juil. 2009 01h00 HE | BiPar Sciences
PARIS and SOUTH SAN FRANCISCO, Calif., July 17, 2009 (GLOBE NEWSWIRE) -- Sanofi-aventis (EURONEXT:SAN) (NYSE:SNY) and its wholly owned subsidiary, BiPar Sciences, today announced the initiation of the...
Investigational Cancer Drug BSI-201 Showed Clinical Benefit in 62% of Patients With Triple-Negative Metastatic Breast Cancer and Significantly Prolonged Survival
31 mai 2009 08h30 HE | BiPar Sciences
PARIS and BRISBANE, Calif., May 31, 2009 (GLOBE NEWSWIRE) -- Sanofi-aventis (EURONEXT:SAN) (NYSE:SNY) and its fully owned subsidiary, BiPar Sciences, today announced results from a randomized Phase 2...
In Prüfung befindlicher PARP-Inhibitor von BiPar Sciences, BSI-201, im Scheinwerferlicht der ASCO-Vollversammlung
20 mai 2009 03h00 HE | BiPar Sciences
BRISBANE, Kalifornien und PARIS, 20. Mai 2009 (GLOBE NEWSWIRE) -- Die Ergebnisse der Phase II einer klinischen Studie von BiPar Science - einem Tochterunternehmen im Besitz von sanofi-aventis - über...
BiPar Sciences' Investigational PARP Inhibitor, BSI-201, to be Highlighted During ASCO's Plenary Session
18 mai 2009 13h56 HE | BiPar Sciences
BSI-201 Phase II Data in Metastatic Triple-Negative Breast Cancer Featured At ASCO Press Briefing; Study Results Will be Released On Sunday, May 31, 2009, At 8:30 a.m. EDT (Orlando, FL)...
BSI-201, le nouveau inhibiteur PARP de BiPar Sciences, sera un moment fort de la séance plénière du congrès annuel
18 mai 2009 13h56 HE | BiPar Sciences
Les données de phase II du BSI-201 dans le cancer du sein métastatique triple négatif seront présentées lors d'une conférence de presse officielle de l'ASCO et intégrées au programme de formation «...
BiPar Sciences' Investigational PARP Inhibitor, BSI-201, to be Highlighted During ASCO's Plenary Session
18 mai 2009 13h21 HE | BiPar Sciences
BRISBANE, Calif. and PARIS, May 18, 2009 (GLOBE NEWSWIRE) -- Results from a Phase II clinical trial of BiPar Sciences' -- a wholly-owned sanofi-aventis subsidiary -- lead PARP inhibitor, BSI-201, will...
Sanofi-aventis to Acquire BiPar Sciences, a US Biopharmaceutical Company
15 avr. 2009 03h01 HE | BiPar Sciences
BRISBANE, Calif. and PARIS, April 15, 2009 (GLOBE NEWSWIRE) -- Sanofi-aventis (EURONEXT:SAN) (NYSE:SNY) announced today that it has signed a binding agreement for the acquisition of BiPar Sciences,...
BiPar Sciences to Present At the 11th Annual BIO CEO & Investor Conference in New York City
03 févr. 2009 09h30 HE | BiPar Sciences
BRISBANE, Calif., Feb. 3, 2009 (GLOBE NEWSWIRE) -- BiPar Sciences, Inc., a privately held biopharmaceutical company developing PARP inhibitors as novel cancer therapies, announced today that President...
BiPar Sciences Raises $20 Million to Advance Clinical Programs
12 janv. 2009 09h00 HE | BiPar Sciences
BRISBANE, Calif., Jan. 12, 2009 (GLOBE NEWSWIRE) -- BiPar Sciences, Inc., a privately held biopharmaceutical company developing PARP inhibitors as novel cancer therapies, announced today it has raised...
BiPar Sciences to Present At the 27th Annual JP Morgan Healthcare Conference in San Francisco
07 janv. 2009 09h00 HE | BiPar Sciences
BRISBANE, Calif., Jan. 7, 2009 (GLOBE NEWSWIRE) -- BiPar Sciences, Inc., a privately held biopharmaceutical company developing PARP inhibitors as novel cancer therapies, announced today that Hoyoung...